Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder

The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the partners decided against further development in this indication The post Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder appeared first on…

Read More

Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug

Sanofi is licensing a RadioMedix radiopharmaceutical in development for neuroendocrine tumors. The French pharmaceutical giant is responsible for global commercialization of the therapy, a potential competitor to the Novartis radiopharmaceutical Lutathera. The post Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug appeared first on MedCity News.

Read More

Links

Should the US privatize the postal service? 4 key themes of IRA’s Part D redesign.Acemoglu: A Renewed Liberalism.In-kind vs. cash payments for long-term care insurance.RFK Jr.: “I believe that vaccines play a critical role in healthcare”

Read More

Understanding the Intersection of Medicaid and Work: An Update

Amid renewed interest in Medicaid work requirements as part of a broader legislative package designed to significantly reduce federal Medicaid spending, KFF has updated its analysis of the work status and demographic characteristics of Medicaid enrollees with the latest data. Data show that, in 2023, 92% of Medicaid adults were either working full or part-time…

Read More